Biotech Values

[DewDiligence]

>> The fact that the 90% of the patients treated with Macugen lost 6 lines, vs. 78% for the placebo, doesn't look good. On the other hand, the percentages don't add up to 100%, so I am probably misreading. <<

vieuxblue: The entries in the efficacy table are cumulative, --each row includes all of the patients in higher rows. Referring to the bottom row in the efficacy table, the figures shown are the percentages of patients who did better than a loss of 6 lines. In other words, 10% (100-90) of patients lost 6+ lines on Macugen while 22% (100-78) lost 6+ lines on placebo. (A loss of 6+ lines is considered “severe.”)

--
Regarding OXGN vs GENR (#669), it is not a zero-sum game. Although these companies are in competition to some degree, it is probable that both will be good investments. GENR has a broader pipeline and is further along in their AMD program; on the other hand, OXGN is more earnest than GENR about their cancer program and OXGN has a lower valuation, especially after the price decline of the past few days. My advice is to buy both companies, as these prices may not last. (Do your own DD of course.) Regards, Dew